Celularity, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-09-01
- Employees
- 225
- Market Cap
- $66.1M
- Website
- http://www.celularity.com
Clinical Trials
17
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
- Conditions
- Astrocytoma, Grade IVGlioblastoma MultiformeGlioblastomaGiant Cell Glioblastoma
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Celularity Incorporated
- Registration Number
- NCT05218408
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Scripps Health, La Jolla, California, United States
🇺🇸Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
- Conditions
- Glioblastoma MultiformeAnalgesicsPeripheral Nervous System AgentsPhysiological Effects of DrugsAnalgesics, Non-narcoticAstrocytoma, Grade IVGiant Cell GlioblastomaCyclophosphamideAntiviral AgentsImmunosuppressive Agents
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 3
- Registration Number
- NCT04489420
- Locations
- 🇺🇸
The Univeristy of Texas MD ANderson Cancer Center, Houston, Texas, United States
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
- Conditions
- Coronaviridae InfectionsImmunologic DiseaseAntiviral AgentsPneumoniaVirus DiseaseAnti-infective AgentsCoronavirus InfectionRespiratory Tract DiseaseRespiratory Tract InfectionsRNA Virus Infections
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT04365101
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Scripps Health, San Diego, California, United States
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
- Conditions
- Leukemia in RemissionRelapsed Adult AMLNeoplasmsImmunosuppressive AgentsAnalgesics, Non-narcoticAnti-infective AgentsAnalgesicsLeukemia, MyeloidLeukemia, Myeloid, AcuteImmunologic Factors
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT04310592
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- Next